The Claim
In diet-induced obese mice, antibody blockade of activin type II receptors with bimagrumab (20 mg/kg weekly) increases lean mass by approximately 8–10% and reduces fat mass by 30%, while co-administration with the GLP-1 receptor agonist semaglutide (120 µg/kg daily) preserves lean mass and enhances fat mass loss to 70% over a 14-day period under calorie restriction.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice on a restricted diet, treatment with bimagrumab increases lean body mass by 8–10% and decreases fat mass by 30%; when combined with semaglutide, lean mass is maintained and fat mass decreases by 70% over 14 days.
See the scientific wording
In diet-induced obese mice, antibody blockade of activin type II receptors (bimagrumab, 20 mg/kg weekly) increases lean mass by approximately 8–10% and reduces fat mass by 30%, while co-administration with the GLP-1 receptor agonist semaglutide (120 µg/kg daily) preserves lean mass and enhances fat mass loss to 70% over 14 days, suggesting a synergistic effect on body composition during calorie restriction.
Blocking a muscle growth inhibitor lets muscles grow bigger even when the body is losing weight, and this also signals fat tissue to burn more fat. When another drug that reduces appetite is added, the fat burns even faster while the muscles stay protected.
What the research says
1 studyIn obese mice, a drug that blocks a muscle growth inhibitor made muscles bigger and fat smaller. When combined with another weight-loss drug, it kept all the muscle while making even more fat disappear — exactly as the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.